A single-blind cross over study investigating the efficacy of standard and controlled release levodopa in combination with entacapone in the treatment of end-of-dose effect in people with Parkinson's disease

Parkinsonism and Related Disorders

Volumn 17, Issue 7, 2011, Pages 533-536

  Iansek, R ^a,b   Danoudis, M ^b  

^a Elsternwick Private Hospital   (Australia)

^b Kingston Centre   (Australia)

Author keywords

Controlled release levodopa; Entacapone; Levodopa; Parkinson's disease; Wearing off

Indexed keywords

DOPA DECARBOXYLASE INHIBITOR; ENTACAPONE; LEVODOPA;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

AGED; ANTIPARKINSON AGENTS; CATECHOLS; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; DYSKINESIAS; FEMALE; HUMANS; LEVODOPA; MALE; NITRILES; PARKINSON DISEASE; SINGLE-BLIND METHOD;

EID: 79960224445     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2011.04.012     Document Type: Article

References (26)

1. Hauser R., Panisset M., Abbruzzese G., Mancione L., Dronamraju N., Kakarieka A. Double-blind trial of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa in early Parkinson's disease. Mov Disord 2009, 24:541-550.
2. Schapira A.H. Treatment options in the modern management of Parkinson's disease. Arch Neurol 2007, 64:1083-1088.
3. Poewe W. The role of COMT inhibition in the treatment of Parkinson's disease. Neurology 2004, 62:S31-S38.
4. Lang A., Lozano A. Parkinson's disease. N Engl J Med 1998, 339:1130-1143.
5. Obeso J., Rodriguez-Oroz M., Chana P., Lera G., Rodriguez M., Olanow C. The evolution and origin of motor complications in Parkinson's disease. Neurology 2000, 55:S13-S20.
6. Ruottinen H.M., Rinne U.K. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to Levodpa therapy in advanced Parkinson's disease. Clin Neuropharmacol 1996, 19:283-296.
7. Horstink M., Tolosa E., Bonuccelli U., Deuschl G., Friedman A., Kanovsky P., et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol 2006, 13:1186-1202.
8. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997, 42:747-755. Parkinson Study Group.
9. Schrag A. Entacapone in the treatment of Parkinson's disease. Lancet Neurol 2005, 4:366-370.
10. Paija O., Laine K., Kultalahti E., Leinonen M., Huupponen R., Gordin A., et al. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. Clin Neuropharmacol 2005, 28:115-119.
11. Piccini P., Brooks D., Korpela K., Pavese N., Karlsson M., Gordin A. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry 2000, 68:589-594.
12. Yeh K.C., August T.F., Bush D.F., Lasseter K.C., Musson D.G., Schwartz S., et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology 1989, 39:25-38.
13. Hammerstad J.P., Woodward W.R., Nutt J.G., Gancher S.T., Block G.A., Cyhan G. Controlled release Levodopa/Carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients. Clin Neuropharmacol 1994, 17:429-434.
14. Lang A.E., Lees A. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002, 17:S23-S37.
15. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992, 55:181-184.
16. Podsiadlo D., Richardson S. The timed " Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991, 39:142-148.
17. Morris S., Morris M.E., Iansek R. Reliability of measurements obtained with the timed " Up & go" test in people with Parkinson disease. Phys Ther 2001, 81:810-818.
18. Goetz C.G., Stebbins G.T., Shale H.M., Lang A.E., Chernik D.A., Chmura T.A., et al. Utility of an objective dyskinesia rating-scale for Parkinsons-disease - interrater and intrarater reliability assessment. Mov Disord 1994, 9:390-394.
19. Fahn S., Elton R. Unified Parkinson's disease rating scale. Recent Developments in Parkinson's disease 1987, 153-163. MacMillan, New York. S. Fahn (Ed.).
20. Jenkinson C., Fitzpatrick R., Peto V. The Parkinson's disease questionnaire (PDQ39): development and validation of a Parkinson's disease summary index score. Age Ageing 1997, 26:353-357.
21. Brown R.G., Dittner A., Findley L., Wessely S.C. The Parkinson fatigue scale. Parkinsonism Relat Disord 2005, 11:49-55.
22. Morris M.E., Iansek R., Churchyard A. The role of physiotherapy in quantifying movement fluctuations in Parkinson's disease. Aust J Physiother 1998, 44:117-121.
23. Stocchi F., Barbato L., Nordera G., Bolner A., Caraceni T. Entacapone improves the pharmacokinetic and therapeutic response of controlled release Levodopa/Carbidopa in Parkinson's patients. J Neural Transm 2004, 111:173-180.
24. Keranen T., Gordin A., Karlsson M., Korpela K., Pentikainen P., Rita H., et al. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 1994, 46:151-157.
25. Koller W.C. Pharmacologic treatment of parkinsonian tremor. Arch Neurol 1986, 43:126-127.
26. Brooks D., Sagar H. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 2003, 74:1071-1079.